CaMKII Phosphorylation Regulates Synaptic Enrichment of Shank3

https://doi.org/10.1523/ENEURO.0481-20.2021

Cite as: eNeuro 2021; 10.1523/ENEURO.0481-20.2021
Received: 9 November 2020
Revised: 12 January 2021
Accepted: 19 January 2021

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.
Title: CaMKII phosphorylation regulates synaptic enrichment of Shank3.

Abbreviated title: Shank3 regulation by CaMKII phosphorylation

Author names and affiliations, including postal codes
- Jaehoon Jeong, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD 20892, USA.
- Yan Li, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD 20892, USA.
- Katherine W. Roche, National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health, Bethesda, MD 20892, USA.

Corresponding author email address: rochek@ninds.nih.gov

Number of pages: 22 pages.

Number of figures, tables, multimedia, and 3D models: 5 figures and 2 extended figure.

Number of words for abstract, introduction, and discussion:
- 190 words for abstract, 648 words for introduction, and 1322 words for discussion.

Conflict of interest statement: The authors declare no competing financial interests.

Acknowledgments: We thank John D. Badger II and all other lab colleagues for assistance and discussion. This research was supported by the NINDS Intramural Research Program.
Abstract

SHANK3 is a large scaffolding protein in the postsynaptic density that organizes protein networks, which are critical for synaptic structure and function. The strong genetic association of SHANK3 with autism spectrum disorder (ASD) emphasizes the importance of SHANK3 in neuronal development. SHANK3 has a critical role in organizing excitatory synapses and is tightly regulated by alternative splicing and posttranslational modifications. In this study, we examined basal and activity-dependent phosphorylation of Shank3 using mass spectrometry analysis from in vitro phosphorylation assays, in situ experiments, and studies with cultured neurons. We found that Shank3 is highly phosphorylated, and we identified serine 782 (S782) as a potent CaMKII phosphorylation site. Using a phosphorylation state-specific antibody, we demonstrate that CaMKII can phosphorylate Shank3 S782 in vitro and in heterologous cells upon co-transfection with CaMKII. We also observed an effect of a nearby ASD-associated variant (Shank3 S685I), which increased S782 phosphorylation. Notably, eliminating phosphorylation of Shank3 with a S782A mutation increased Shank3 and PSD-95 synaptic puncta size without affecting Shank3 colocalization with PSD-95 in cultured hippocampal neurons. Taken together, our study revealed that CaMKII phosphorylates Shank3 S782 and that the phosphorylation affects Shank3 synaptic properties.

Significance Statement

The precise regulation of scaffolding proteins is important for both neuronal development and dysregulation underlies some neurodevelopmental disorders. As an excitatory synapse scaffolding protein, SHANK3 plays a critical role in synapse structure and function and has a strong genetic linkage to ASD. In this report, we examined the fine regulation of Shank3 by phosphorylation. Our study characterizes a CaMKII phosphorylation site on Shank3 (S782) in vitro, in situ, and in neurons. The Shank3 phosphorylation is modulated by a neighboring ASD-associated mutation. Furthermore, S782
phosphorylation is involved in Shank3 synaptic enrichment. These findings reveal molecular mechanisms of SHANK3 function at excitatory synapses and a potential role in ASD etiology.

**Introduction**

Shank/ProSAP family proteins consist of three isoforms (SHANK1, SHANK2, and SHANK3) and help organize protein networks in the postsynaptic density (PSD) (Ehlers, 1999; Sheng and Kim, 2000). Shank family proteins have five conserved domains: an ankyrin repeat domain (ANK), Src homology 3 (SH3) domain, a PSD-95/Disc large/ZO-1 (PDZ) domain, a proline-rich region, and a sterile alpha motif (SAM) domain (Sheng and Kim, 2000). More than 30 synaptic proteins, including receptors, ion channels, cytoskeletal proteins, signaling molecules, and enzymes, have been identified to interact with Shank3 (Kreienkamp, 2008). These interactions are mediated by the conserved domains in Shank3; and, due to the similarity of protein domains, many of the identified binding partners are shared among all Shank family proteins.

A variety of *SHANK3* gene defects have been revealed in patients with autism spectrum disorder (ASD) (Jiang and Ehlers, 2013; Ruzzo et al., 2019; Satterstrom et al., 2020). Chromosomal disruptions of the *SHANK3* gene within the critical region of 22q13.3 deletion syndrome (Phelan-McDermid syndrome, PMS) have been widely studied (Wilson et al., 2003), and chromosomal microdeletions of *SHANK1* and *SHANK2* genes have also been reported (Pinto et al., 2010; Sato et al., 2012). Genome and exome sequencing studies have revealed inherited or de novo mutations associated with ASD. These point mutations include missense, nonsense, frame shift, and splice site mutations that disrupt SHANK3 protein expression. The ASD-associated point mutations are primarily found in the *SHANK3* gene, although cases identified in the *SHANK1* and *SHANK2* genes are also accumulating (Sato et al., 2012; Jiang and Ehlers, 2013).
Because SHANK3 plays such a critical role in synapse structure and function and due to its close genetic
linkage to ASD, understanding the precise molecular mechanisms that regulate SHANK3 is important.
Since SHANK3 is a huge molecular weight protein with multiple domains, people have mostly focused
on characterizing the synaptic role of the interaction between the individual SHANK3 protein domains
and their binding partners by utilizing in vitro experiments combined with knock-in or knock-out animal
models (Jiang and Ehlers, 2013). It is known that phosphorylation of scaffolding proteins is an important
regulatory mechanism for protein interactions, subcellular distribution, and physiological functions
(Iasevoli et al., 2013). For instance, PSD-95, an excitatory synapse scaffolding protein, has multiple
phosphorylation sites, which are targeted by several kinases, such as JNK1, CDK5, and GSK3β, to
modulate its synaptic accumulation and promote receptor clustering (Morabito et al., 2004; Kim et al.,
2007; Nelson et al., 2013). More recently, the regulation of Shank3 by phosphorylation of one residue,
serine 685 (S685) has been reported using a variety of techniques (Wang et al., 2019; Perfitt et al., 2020a).
This particular site coincides with an ASD-associated variant site, and the phosphorylation and rare
variant are associated with the recruitment of Abelson interactor 1 (ABI1) to Shank3 protein. These
studies demonstrated S685 is phosphorylated in a transgenic mouse model (Wang et al., 2019), that
CaMKII and PKA can phosphorylate Shank3 S685 in vitro (Wang et al., 2019; Perfitt et al., 2020a), that
the phosphorylation is required for the ABI1 interaction with Shank3 (Wang et al., 2019; Perfitt et al.,
2020a).

In this study, we characterized basal phosphorylation of Shank3 in heterologous cells and also upon
CaMKII activation. CaMKII is an abundant protein in neurons and involved in many critical regulatory
pathways in the PSD (Hell, 2014). By conducting a series of mass spectrometry analyses with in vitro, in
situ, and neuronal samples, we found Shank3 is highly phosphorylated under basal conditions and that the
serine 782 (S782) residue on Shank3 is a potent CaMKII phosphorylation site. We demonstrated CaMKII
directly phosphorylates Shank3 S782 by probing immunoblots with a S782 phosphorylation state-specific
antibody. We did not observe any effects of Shank3 S782 phosphorylation on protein binding to the
Shank3 PDZ domain. However, strikingly in hippocampal cultured neurons, we observed Shank3 S782 phosphorylation regulates Shank3 enrichment in synaptic spines and the size of PSD-95 defined synapses.

Materials and Methods

Plasmids and antibodies.

HA-tagged rat Shank3 plasmid was kindly provided by Dr. Eunjoon Kim. CaMKII and CaMKII R42K plasmids were characterized in our previous studies. pClneo-GKAP-myc plasmids were used for biochemical and imaging experiments. The commercial antibodies used in this study were rabbit anti-Shank3 (Synaptic System, 162 302), mouse anti-PSD-95 (Neuromab, clone K28/43), mouse anti-myc (Cell Signaling, clone 9B11), rabbit anti-HA (Abcam, ab9110), rat anti-HA (Roche), rabbit anti-β tubulin (Sigma, T2200), and mouse anti-β actin (ABM, G043).

Mass spectrometry.

In-gel samples were digested with chymotrypsin at 25°C for 18 hours. Peptides were extracted and desalted before being injected into a nano-LC/MS/MS system where an Ultimate 3000 HPLC (Thermo-Dionex) was coupled to an Orbitrap Elite mass spectrometer (Thermo Scientific) via an Easy-Spray ion source (Thermo Scientific). Peptides were separated on a ES802 Easy-Spray column (75-μm inner diameter, 25 cm length, 3 μm C18 beads; Thermo Scientific) with a 25-min linear gradient of 2–27% mobile phase B (mobile phase A: 2% acetonitrile, 0.1% formic acid; mobile phase B: 98% acetonitrile, 0.1% formic acid). The HPLC flow rate was 300 nl/min.

Thermo Scientific Orbitrap Elite mass spectrometer was operated in positive data-dependent LC-MS/MS mode. The resolution of the survey scan was set at 60k at m/z 400. The m/z range for MS scans was 300–1600. For MS/MS data acquisition, the decision-tree mode was activated, the minimum signal intensity
required to trigger MS/MS scan was 1e4, the top ten most abundant ions were selected for product ion analysis, the isolation width was 1.9 m/z, and the dynamic exclusion window was 9 sec.

Xcalibur RAW files were converted to peak list files in mgf format using Mascot Distiller. Database search was performed using Mascot Daemon (2.4.0) against NCBI nc_Human database. Spectra of phosphopeptides were manually checked.

**GST fusion protein production.**

Shank3 fragments were subcloned into the pGEX-4T plasmid and transformed to BL21 bacterial cells. Bacterial cultures were grown at 37°C to an absorbance at 600 nm of 1.1–1.2 of the culture media. 50 μM isopropyl β-d-thiogalactopyranoside (IPTG) was added to the cultures and incubated at 16°C overnight to induce fusion protein expression. The bacterial pellets were then lysed in a Tris-buffered saline (TBS) buffer containing protease inhibitors (Roche), 100 μg/ml lysozyme, 15 mM dithiothreitol (DTT), 10 mM ethylenediaminetetraacetic acid (EDTA), and 1.5% sarkosyl. The sonicated lysate was neutralized with Triton X-100 to a final concentration of 4%. The lysates were incubated with glutathione-Sepharose 4B (GE Healthcare) for 1 hour at 4°C and subsequently washed with TBS buffer containing 1 mM EDTA and 0.1% Triton X-100.

**In vitro kinase assay and GST-pulldown.**

GST fusion proteins were phosphorylated in 10 mM HEPES, (pH 7.0), 20 mM MgCl₂, 50 μM ATP and 1 pmol of [γ-32P] ATP (3,000 Ci mmol⁻¹) with 50 ng of purified CaMKII catalytic subunit (Promega). In vitro kinase assays were performed at 30°C for 15 min. Proteins were eluted from the glutathione-Sepharose resin and resolved by SDS-PAGE and analyzed by immunoblotting.
For GST-pulldown, the cell lysates were prepared in hypoosmotic buffer (20 mM Tris-HCl, pH 8.8, 5 mM EDTA, 1% DOC). GST fusion proteins were incubated with the lysate at 4°C overnight. The samples were resolved by SDS-PAGE and analyzed by immunoblotting.

**Transfection and immunoblot.**

HEK293 cells were transfected with Lipofectamine\(^{2000}\) and 2 days after transfection the cells were lysed in a TBS buffer containing 150 mM NaCl, 50 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1% Triton X-100. Lysates were centrifuged at 16,000 g for 15 min at 4°C and supernatant were used for the analysis. For coimmunoprecipitation, lysates were incubated with an appropriate antibody at 4°C overnight and protein-A-Sepharose beads (GE Healthcare) at 4°C for 1 hour. All chemiluminescence blots were captured with a ChemiDoc\(^{TM}\) Imaging System (Bio-Rad).

**Neuronal cultures.**

For biochemical analyses and immunocytochemistry experiments, we used primary cultured cortical and hippocampal neurons from embryonic day 18 (E18) Sprague Dawley rats of either sex. Briefly, embryonic hippocampal or cortical tissues were dissociated at 37°C for 30 min by 0.05% trypsin in 10 mM HBSS containing 1.37 mg/ml DNase I. Neurons were plated and maintained in serum-free Neurobasal Medium supplemented with 2% (vol/vol) B-27 and 2 mM L-Glutamine. We adhered to the guidelines of the National Institutes of Health's Animal Care and Use Committee regarding the care and use of animals for this study (protocol #1171).

**Immunocytochemistry.**
Cultured hippocampal neurons were grown on glass coverslips precoated with poly-D-lysine (Sigma). Neurons were transfected with the indicated plasmids with Lipofectamine® at DIV 12-15 and prepared for analysis at DIV 19-21, if not described otherwise. To label HA-SHANK3, the transfected neurons were fixed with 4% paraformaldehyde and 4% sucrose in PBS for 10 min. After fixation, the neurons were permeabilized with 0.25% Triton X-100 in PBS and blocked with 10% goat serum. The neurons were labeled with rat anti-HA antibody and Alexa 555-conjugated anti-rat secondary antibody (Molecular Probes). For endogenous PSD-95 and Shank3 staining, neurons were prepared as above, then labeled with anti–PSD-95 (NeuroMab, clone K28/43) and anti-Shank3 (Synaptic System, 162 302).

For analysis, regions from three dendrites per each neuron were collected and quantified by the fluorescence intensity of target proteins. All images were captured with a 63× objective on a Zeiss LSM 510 confocal microscope and analyzed with the Image J and MetaMorph Version 7.

Experimental design and statistical analyses.

Data analysis was carried out in Image Lab™ Software (Bio-Rad) or GraphPad Prism (GraphPad Software).

Results

Shank3 is a highly phosphorylated protein.

Phosphorylation is one of the most common regulatory mechanisms to modulate synaptic protein interactions and subcellular localization. Since SHANK3 is a large essential scaffolding protein in the PSD, we sought to investigate phosphorylation-mediated SHANK3 regulation. To establish the SHANK3 phosphorylation profile, we expressed HA-Shank3 in HEK293 cells and HA-Shank3 was
immunoprecipitated for mass spectrometry analysis. In the mass spectrometry results, 87% of the Shank3 protein sequence was recovered and, notably, multiple basal phosphorylation sites were observed (Fig. 1A). Multiple phosphorylation sites on the Shank3 protein have been previously reported in several studies by analyzing various kinds of samples (Thomas et al., 2005; Huttlin et al., 2010; Trinidad et al., 2012; Nagai et al., 2016; Wang et al., 2019). Although, due to its large gene and protein size, consequences of these phosphorylation events for Shank3 function have been rarely identified at the molecular and cellular levels (Wang et al., 2019).

We next compared the Shank3 basal phosphorylation sites with ASD-associated serine/threonine variants in annotated public databases to find any ASD-associated phosphorylation site. Since SHANK3 is the most well studied ASD-associated gene, 249 rare variants are found in databases (https://gene.sfari.org/database/human-gene/SHANK3). Among these variants, 11 missense and 7 frameshift variants occurred on serine/threonine sites, which might lead to disruption of serine/threonine phosphorylation (Fig. 1B). Other than serine 686 (serine 685 in rodent)(Wang et al., 2019), we did not find any overlap between the ASD-associated SHANK3 serine/threonine variants and identified Shank3 phosphorylation sites in phosphoproteomic databases (https://www.phosphosite.org/proteinAction.action?id=14451&showAllSites=true) and our Shank3 basal phosphorylation sites (Fig. 1A and 1B). Thus, to our surprise, we did not identify ASD-associated SHANK3 serine/threonine phosphorylation that are also in ASD databases. It could be that this negative correlation results from differing protocols in collecting samples or limited Shank3 protein coverage for phospho-proteomic analysis, but thus far the data sets are distinct.

CaMKII phosphorylates Shank3 on serine 782.

As we observed multiple basal phosphorylation sites on Shank3, we next investigated if CaMKII phosphorylates Shank3. CaMKII is the most abundant synaptic kinase, and we therefore decided to
characterize it first. To identify CaMKII phosphorylation sites on Shank3, we performed a series of mass spectrometry analyses. First, we incubated GST-Shank3 fusion proteins, which cover regions of the Shank3 protein from aa 1-1265, with purified CaMKII and adenosine 5′-triphosphate (ATP) for in vitro kinase assays. Next, full-length HA-Shank3 and CaMKII were expressed in HEK293 cells, and HA-Shank3 was immunoprecipitated using anti HA-antibody. Lastly, we treated cultured rat cortical neurons with KCl to increase endogenous CaMKII activity (Bemben et al., 2014), and endogenous Shank3 were enriched from the neuron lysates by immunoprecipitation using anti-Shank3 antibody. In each of these three experimental paradigms, the isolated protein was analyzed using mass spectrometry. Figure 2B shows a schematic of the experimental procedure for the analysis of the samples from the cultured neurons and its representative MS/MS spectrum (Fig. 2B). In these mass spectrometry analyses, we found phospho-peptides corresponding to phosphorylation on Shank3 serine 782 (S782) from all different types of samples (Fig. 2, Fig. 2-1C and Fig. 2-1D). These results show a reliability of Shank3 S782 phosphorylation by CaMKII (Fig. 1A). We also observed the Shank3 serine 685 phosphorylation (De Rubeis et al., 2014; Wang et al., 2019) from the in vitro kinase assay samples (Fig. 2-1B), but not from the cell line and cultured neuron samples.

To examine the phosphorylation of Shank3 S782 further, we generated a phosphorylation state-specific antibody, pS782 antibody. GST-Shank3 (473-903) WT or S782A fusion proteins were incubated with CaMKII and ATP in vitro. The samples were resolved by SDS/PAGE and analyzed by immunoblotting with the pS782 antibody. We observed CaMKII activity-dependent immunoreactivity for GST-Shank3 WT and the serine to alanine mutation completely eliminated the immunoreactivity (Fig. 2C). To determine if full-length Shank3 can be phosphorylated by CaMKII, we cotransfected HA-Shank3 and constitutively active CaMKII (CaMKII T286D) or inactive CaMKII (CaMKII R42K) in HEK293 cells. HA-Shank3 was immunoprecipitated using HA-antibody, and the immunoprecipitates were resolved by SDS/PAGE and analyzed by immunoblotting. The immunoblots showed that both active and inactive CaMKII are coimmunoprecipitated with HA-Shank3 as shown previously (Perfitt et al., 2020b), but the
pS782 immunoreactivity for HA-Shank3 was specifically increased upon active CaMKII cotransfection, which was not the case for the inactive CaMKII R42K cotransfection (Fig. 2D). Notably, the CaMKII binding motif, R^{495}-R^{505}-K^{511} (Perfitt et al., 2020b) has been characterized and the Shank3 S782 phosphorylation site is not far from the binding motif, further implicating CaMKII regulation (Fig. 2A). All of these results indicate that CaMKII regulates Shank3 via direct phosphorylation on S782.

An ASD-associated Ser685Ile mutation increases CaMKII-mediated Shank3 S782 phosphorylation.

Noticeably, Shank3 S782 is in close proximity to an ASD-associated Ser686Ile (S686I) missense variant (De Rubeis et al., 2014) (Fig. 3A). Therefore, we next asked if the S686I (S685I in rodent) mutation affects Shank3 S782 phosphorylation. To answer this question, we cotransfected HA-Shank3 (WT or S685I) and constitutively active CaMKII (CaMKII T286D) in HEK293 cells. The cell lysates were resolved by SDS/PAGE and analyzed by immunoblotting. Interestingly, the immunoblots showed that the pS782 immunoreactivity for HA-Shank3 S685I was increased compared with HA-Shank3 WT (Fig. 3B). We were curious whether the increased S782 phosphorylation on HA-Shank3 S685I is due to an enhanced CaMKII interaction. To examine this, we cotransfected HA-Shank3 WT or S685I and constitutively active CaMKII in HEK293 cells. HA-Shank3 were immunoprecipitated using HA-antibody, and coimmunoprecipitated CaMKII was analyzed by immunoblotting. The immunoblots showed that CaMKII binding with HA-Shank3 S685I was not altered compared with HA-Shank3 WT (Fig. 3C). To explore further, GST-Shank3 (473-903) WT or S685I fusion proteins that lack the CaMKII binding site were incubated with CaMKII and ATP in vitro. The samples were resolved by SDS/PAGE and analyzed by immunoblotting with pS782 antibody. We observed that the pS782 immunoreactivity for GST-Shank3 473-903 WT and S685I are comparable (Fig. 3D). These results indicate that in situ context is important for the Shank3 S782 phosphorylation.
Shank3 S782 phosphorylation does not affect PDZ domain binding.

Many studies have shown that the SHANK3 PDZ domain is important for protein interactions with several binding partners, such as GKAPs, PSD-93, mGluR1/5, and PLC-β3 (Sheng and Kim, 2000; Jiang and Ehlers, 2013). Since the PDZ interactions can be regulated by phosphorylation and S782 is about 100 amino acids away from the PDZ domain, we tested whether S782 phosphorylation affects the Shank3 interaction with its binding partners.

We expressed myc-GKAP in HEK293 cells and the cell lysates were incubated with GST-Shank3 (473-903) fusion proteins (WT, S782A, or S782D) for pulldown assays. Because GST-Shank3 (473-903) fusion proteins do not contain a Homer binding region, we used Homer1b-myc as a negative control. The isolated beads were resolved by SDS/PAGE and analyzed by immunoblotting. The amount of GST fusion proteins was visualized by Coomassie Brilliant Blue staining. Contrary to our expectations, neither S782A nor S782D showed changes compared to WT in binding with myc-GKAP (Fig. 4A). AMPAR subunits are also known to interact with Shank3 via its PDZ domain (Uchino et al., 2006; Jiang and Ehlers, 2013). To examine this, we incubated GST-Shank3 (473-903) fusion proteins (WT, S782A, or S782D) with rat brain P2 lysates for pulldown assays. The isolated beads were resolved by SDS/PAGE and analyzed by immunoblotting. The amount of GST fusion proteins was visualized by Ponceau staining on the same membrane. We did not observe any changes in binding with endogenous GluA1/2 receptors (Fig. 4B).

We reexamined the pulldown results using coimmunoprecipitation in intact cells. We cotransfected HA-Shank3 (WT, S782A, or S782D) and myc-GKAP in HEK293 cells. HA-Shank3 were immunoprecipitated from the cell lysates and resolved by SDS/PAGE, and coimmunoprecipitated myc-GKAP was analyzed by immunoblotting. We did not observe any significant differences in HA-Shank3 (WT, S782A, or S782D) and myc-GKAP interactions (Fig. 4C left and Fig. 4D top). To evaluate potential effects of cellular phosphorylation by CaMKII, we cotransfected HA-Shank3 WT and myc-GKAP with or without constitutively active CaMKII in HEK293 cells. We did not see any changes in HA-Shank3 and myc-
GKAP interactions upon CaMKII transfection (Fig. 4C \textit{right} and Fig. 4D \textit{bottom}). All these results indicate that Shank3 S782 phosphorylation is not necessarily associated with the Shank3 PDZ interactions.

**Shank3 S782 phosphorylation affects Shank3 enrichment and synapse size.**

To examine any effect of Shank3 S782 phosphorylation on synaptic properties, cultured rat hippocampal neurons were transfected with HA-Shank3 (WT, S782A, or S782D) at DIV 12 and the neurons were prepared to label HA-Shank3 and endogenous PSD-95 at DIV 20 for immunofluorescence confocal microscopy. Images of the secondary dendritic regions were captured, and the fluorescence signal was adjusted to measure the perimeter of synaptic puncta (Fig. 5A and 5B). We compared HA-Shank3 S782A and S782D to HA-Shank3 WT to investigate the site specific effect on synapses. Interestingly, the phosphodeficient mutant, HA-Shank3 S782A, showed increased synaptic puncta size and endogenous PSD-95 puncta size in the HA-Shank3 S782A expressing dendrites was also increased (Fig. 5C). Colocalization of HA-Shank3 S782A or S782D with endogenous PSD-95 was not diminished compared with HA-Shank3 WT (Fig. 5C).

We showed that the ASD-associated Shank3 S685I mutation increases Shank3 S782 phosphorylation (Fig. 3B). To better understand the functional correlation between these two sites, we further examined Shank3 S685I synaptic enrichment and colocalization with PSD-95. Cultured rat hippocampal neurons were transfected with HA-Shank3 (WT or S685I) at DIV 12 and prepared and analyzed as above. We observed that HA-Shank3 S685I shows comparable synaptic puncta size and colocalization with PSD-95 compared with HA-Shank3 WT (Fig. 5D and 5E). In contrast, PSD-95 puncta size was decreased in the HA-Shank3 S685I expressing dendrites (Fig. 5D and 5E), which might partially be the result of impaired synaptic protein recruitment by the Shank3 S685I mutant (Wang et al., 2019).

All these results indicate that Shank3 S782 phosphorylation regulates Shank3 synaptic puncta size as well as associated PSD-95 puncta size, without affecting colocalization of Shank3 and PSD-95.
Discussion

*SHANK3* has been the focus of intense investigation due to its role in neurodevelopmental disorders such as ASD and Phelan McDermid. The characterization of *SHANK3* has revealed a high degree of complexity as it exists in many forms due to alternative splicing and different start sites resulting in a variety of mature proteins. A recent study (Wang et al., 2019) has shown that Shank3 also have a high level of regulation by phosphorylation in vivo, although the relevant kinases and effect of synaptic activity on these phosphorylation events were not explored. In the current study, we used multiple experimental preparations to investigate the regulation of Shank3 by phosphorylation. Using mass spec analyses, we found that full-length Shank3 expressed in HEK293 cells is highly phosphorylated under basal conditions (Fig. 1). Our studies are in agreement with several previous studies that reported phosphorylation sites on Shank3. We initially hypothesized that identified phosphorylation would have considerable overlap with identified disease-associated variants based on one such example in the literature (S685) (De Rubeis et al., 2014; Wang et al., 2019). However, surprisingly, we found the ASD variants did not overlap with any of the reported 55 phosphorylation sites in human *SHANK3*, except the single case.

We explored the relevant kinases targeting *SHANK3*. Because CaMKII is an abundant kinase in neurons and is involved in many critical synaptic events (Hell, 2014), we examined if there was additional phosphorylation of Shank3 upon CaMKII activation. We demonstrated CaMKII phosphorylation of Shank3 S782 using mass spectrometry analysis of three different experimental samples: in vitro CaMKII assays with GST-Shank3 fusion proteins, immunoprecipitated HA-Shank3 from CaMKII expressing HEK293 cells, and enriched endogenous Shank3 from KCl-stimulated cultured cortical neurons (Fig. 2). We cannot completely exclude the possibility of S782 phosphorylation by other synaptic kinases in neurons, but we compared basal HA-Shank3 phosphorylation to CaMKII activated HA-Shank3 phosphorylation in the mass results from cell lines. The only other study reporting a direct
phosphorylation of Shank3 by CaMKII involved in vitro assays assessing phosphorylation of GST-Shank3 (572-691) fusion proteins showing that Shank3 S685 can be phosphorylated by CaMKII (Perfitt et al., 2020a). Because this study looked specifically at a particular region of Shank3, it wasn’t clear if CaMKII had other targets within Shank3. Based on our identification of S782 as a CaMKII site, we generated a phospho-state specific antibody (pS782) to allow analyses of this phosphorylation in situ (Fig. 2 and 3). We used this reagent and observed Shank3 S782 phosphorylation by CaMKII in a cellular context, which supports S782 site specific phosphorylation by CaMKII. Although the phosphoantibody has a limited affinity to analyze endogenous Shank3 S782 phosphorylation in neurons and brain lysates, we demonstrated that CaMKII phosphorylates Shank3 on S782 in situ using cell lines. Although we did not identify additional ASD-associated Shank3 variants that correspond with newly detected phosphorylation sites, we did examine the effect of an ASD-associated variant on S782 phosphorylation. Wang et al., characterized Shank3 S686 as a PKA phosphorylation site and investigated the effect of the de novo S686I ASD-associated variant on synapse and dendritic spine development (Wang et al., 2019). The de novo mutation in an ASD patient, Shank3 S686I, is several amino acids away from S782 and thus was a candidate to exert a potential effect. We evaluated this point mutation and observed an increase in S782 phosphorylation in situ without a robust change in the CaMKII association (Fig. 3B and 3C). However, we didn’t see any changes in Shank3 S782 phosphorylation in the samples from in vitro kinase assays with GST-Shank3 (473-903) WT and S686I fusion proteins (Fig. 3C). This discrepancy points to important factors within the in situ context that regulate Shank3 S782 phosphorylation. All these findings show that the ASD-associated Shank3 S686I mutation can affect the nearby CaMKII-mediated S782 phosphorylation, which indicates that dysregulation of the S686 and S782 phosphorylation may result in a combined pathological mechanism for the ASD development.

To assess the effect of S782 phosphorylation, we first tested whether S782 mutations would affect the Shank3 binding with its well-known PDZ domain binding partners (Uchino et al., 2006; Jiang and Ehlers, 2013). In our results, S782 mutations didn’t alter Shank3 binding with GKAP or AMPARs in biochemical
assays (Fig. 4). Notably, two previous studies found that disruption of Shank3 S685 phosphorylation specifically abolished Shank3-ABI1 binding, but didn’t alter GkAP, cortactin, L-type Ca\(^{2+}\) channel Ca,1.3, or Homer binding (Wang et al., 2019; Perfitt et al., 2020a). Along with these previous findings, our results (Fig. 4) suggest that S782 and S685 are within a region that is not a major regulatory site for Shank3 binding with Homer, cortactin, and other PDZ domain binding partners. More accurate tertiary protein structure of the Shank3 region is required for a better understanding of conformational regulation of relevant protein-protein interactions.

Because Shank3 is a critical scaffolding protein central to the organization of excitatory synapses, we assessed any potential effect of S782 on Shank3 enrichment and synapse size. Using immunofluorescence microscopy, we observed that expressing Shank3 that cannot be phosphorylated on S782 (S782A) increased both Shank3 and PSD-95 synaptic puncta size in dendritic spines compared to WT expression (Fig. 5A, 5B, and 5C). It has been known that Shank3 and GkAP binding is important for Shank3 synaptic localization, and that Shank3 overexpression has a positive correlation with PSD-95 clustering (Naisbitt et al., 1999; Han et al., 2013). However, because S782 phosphorylation didn’t affect binding to PDZ proteins, the increased Shank3 S782A and PSD-95 synaptic puncta size is unlikely to be related with GkAP binding (Fig. 4) (Wang et al., 2019; Perfitt et al., 2020a). Pharmacological activation of global CaMKII in cultured neurons did not change colocalization between endogenous Shank3 and PSD-95 (Fig. 5-1). Since CaMKII is known to phosphorylate multiple targets in synapses, it would be difficult to dissect S782 phosphorylation specific effect of CaMKII pharmacological activation, but these results may imply that S782 phosphorylation specifically but partially regulates the association of Shank3 and PSD-95 in neurons.

As the ASD-associated Shank3 S685I mutation increases Shank3 S782 phosphorylation (Fig. 3B), we also examined the effect of S685I on Shank3 enrichment and synapse size. Interestingly, Shank3 S685I showed comparable synaptic puncta size to Shank3 WT, similar to Shank3 S782D (Fig. 5A, 5C, 5D and 5E). However, Shank3 S685I reduced PSD-95 puncta size without affecting colocalization with PSD-95.
From these results, we conclude that dephosphorylation of Shank3 S782 (S782A) increases Shank3 synaptic enrichment, whereas phosphorylation of Shank3 S782 (S782D) by CaMKII or following the S685I mutation retains Shank3 enrichment and synapse size. Importantly, Shank3 interacts with various synaptic actin signaling molecules, such as α-fodrin, ABI1, and Abp1 for actin nucleation and WASP family verprolin homologous protein (WAVE) complex (Bockers et al., 2001; Qualmann et al., 2004). These interactions are important for spine formation and maturation, and phosphorylation of the ASD-associated residue, S685, is involved in actin regulation (Kuriu et al., 2006; Wang et al., 2019).

Dynamic and differential Shank3 remodeling in the PSD by neuronal activity is highly dependent on the actin cytoskeleton (Kuriu et al., 2006; Tao-Cheng et al., 2016). Since neuronal activity-dependent translocation of CaMKII to the PSD is also well characterized (Shen and Meyer, 1999; Tao-Cheng, 2020), Shank3 S782 may be a CaMKII regulated phosphorylation site that balances the Shank3 association with the actin signaling molecules that are regulated by Shank3 S685 phosphorylation. Further experiments are required to understand more about the possible mechanistic link between these proteins.

In this study, we characterized CaMKII phosphorylation of Shank3 S782 using a variety of assays. Although S782 does not show up in databases as an ASD-associated variant, we did find that Shank3 S782 phosphorylation is affected by the nearby ASD-associated variant, S685I. Furthermore, we found that this variant is involved in Shank3 synaptic enrichment. Because both CaMKII and Shank3 play such critical roles at excitatory synapses during development and activity-dependent plasticity, we think this newly identified regulatory site is worthy of future studies involving in vivo mouse models.
Reference


Figure legends

Figure 1. Shank3 is a highly phosphorylated protein. (A) Basal phosphorylation sites in full-length Shank3 protein identified by mass spectrometry illustrated on a schematic drawing. HA-Shank3 was expressed in HEK293 cells and immunoprecipitated HA-Shank3 was subjected to mass spectrometry analysis. (B) ASD-associated serine/threonine variants found in annotated public databases are depicted on a schematic drawing. Familial variants are indicated in red and de novo variants are indicated in blue. Variants with unknown inheritance pattern are in black.

Figure 2. CaMKII phosphorylates Shank3 on serine 782. (A) Schematic figures denote CaMKII-dependent phosphorylation on Shank3 S782. (B) Cultured rat cortical neurons were treated with 20 µM KCl for 10 min and endogenous Shank3 was enriched by immunoprecipitation using anti-Shank3 antibody. Protein samples were resolved by SDS-PAGE. Samples were in-gel digested and analyzed using the LC/MS/MS method. Representative MS/MS spectrum of the phosphorylated Shank3 peptide found in the samples from cultured rat cortical neurons treated with KCl. MS/MS spectrum from in vitro phosphorylation assays and in situ experiments are presented in Extended Data Figure 2-1. (C) Immunoblot analysis of GST-Shank3 (473-903) WT and S782A fusion proteins that were phosphorylated in vitro with purified CaMKII and probed with pS782 antibody. (D) HA-Shank3 was transfected or cotransfected with constitutively active CaMKII T286D or constitutively inactive CaMKII K42R in...
HEK293 cells. The Shank3 pS782 antibody immunoreactivity in the immunoprecipitates with HA-antibody were analyzed by immunoblotting.

Figure 3. An ASD-associated Shank3 S685I mutation increases CaMKII-mediated Shank3 S782 phosphorylation. (A) Schematic figures denote the ASD-associated Ser685Ile (S685I) mutation and CaMKII-dependent phosphorylation on Shank3 S782. (B) HA-Shank3 WT or S685I were cotransfected with constitutively active CaMKII T286D in HEK293 cells. The Shank3 pS782 antibody immunoreactivity was analyzed by immunoblotting. Quantitative graph represents mean ± SEM (n = 4). *P = 0.0102 using an unpaired t test. (C) HA-Shank3 WT or S685I were cotransfected with constitutively active CaMKII T286D in HEK293 cells. HA-Shank3 was immunoprecipitated with HA antibody and CaMKII T286D was analyzed by immunoblotting. Quantitative graph represents mean ± SEM (n = 4). Statistical significance was calculated using an unpaired t test. n.s., not significant. (D) Immunoblot analysis of GST-Shank3 473-903 WT or S685I fusion proteins that were phosphorylated in vitro with purified CaMKII and probed with pS782 and GST antibody. Quantitative graph represents mean ± SEM (n = 3) and statistical significance was calculated using an unpaired t test. n.s., not significant.

Figure 4. Shank3 S782 phosphorylation does not affect PDZ domain binding. (A) myc-GKAP or Homer1b-myc were expressed in HEK293 cells and the cell lysates were incubated with GST-Shank3 fusion proteins (WT, S782A, or S782D) for pulldown assays. myc-GKAP or Homer1b-myc in the pulldown sample were analyzed by immunoblotting. (B) GST-Shank3 fusion proteins (WT, S782A, or S782D) were incubated with rat brain P2 lysates for pulldown assays. The pulldown samples were analyzed by immunoblotting with indicated antibodies. (C) HA-Shank3 (WT, S782A, or S782D) and myc-GKAP were cotransfected in HEK293 cells (left). HA-Shank3 and myc-GKAP were cotransfected with or without CaMKII in HEK293 cells (right). HA-Shank3 was immunoprecipitated with HA antibody and myc-GKAP was analyzed by immunoblotting. (D) Quantitative graphs represent mean ± SEM (n = 3)
and statistical significance was calculated using one-way ANOVA with Dunnett’s multiple comparison test (top) or an unpaired t test (bottom). n.s., not significant.

**Figure 5.** Shank3 S782 phosphorylation affects Shank3 enrichment and synapse size. (A) HA-Shank3 (WT, S782A, or S782D) was expressed in cultured rat hippocampal neurons. HA-Shank3 was stained with anti-HA and Alexa 555-conjugated secondary antibody (red). Endogenous PSD-95 was labeled with anti-PSD-95 antibody and Alexa 488-conjugated secondary antibody (green). Region from the secondary dendrites are shown (Scale bar, 5 µm). (B) Fluorescence signal was adjusted to measure perimeter of synaptic puncta. (C) Region from the secondary dendrites were analyzed for puncta size and Pearson’s coefficient. Graph indicates mean ± SEM (n = 28 for WT, n = 26 for S782A and S782D). ****P < 0.0001 and ***P < 0.0002 using one-way ANOVA with Dunnett’s multiple comparison test. Colocalization analysis between endogenous Shank3 and PSD-95 upon CaMKII pharmacological activation in neurons are presented in Extended Data Figure 5-1. (D) HA-Shank3 (WT or S685I) was expressed in cultured rat hippocampal neurons. HA-Shank3 and endogenous PSD-95 were stained and analyzed as above. Region from the secondary dendrites are shown (Scale bar, 5 µm). (E) Graph indicates mean ± SEM (n = 24 for WT, n = 30 for S685I). ***P < 0.0002 using an unpaired t test. n.s., not significant.

**Extended Figure legends**

**Figure 2-1.** Mass spectrometry analysis from in vitro phosphorylation assays and in situ experiments. (A) A schematic of the experimental procedure for the analysis of the samples from in vitro phosphorylation assays and in situ experiments. (B, C) Representative MS/MS spectra of the Shank3 S685 and S782 phosphorylated peptide found in the samples from in vitro phosphorylation assays. (D) Representative MS/MS spectrum of the Shank3 S782 phosphorylated peptide found in the samples from in situ experiments.
Figure 5-1. No detectable effect of CaMKII pharmacological activation on the colocalization between endogenous Shank3 and PSD-95 in neurons. (A, B) Cultured rat cortical neurons were treated with 20 µM KCl for 10 min to activate endogenous CaMKII. Endogenous Shank3 was stained with anti-Shank3 and Alexa 555-conjugated secondary antibody (red). Endogenous PSD-95 was labeled with anti-PSD-95 antibody and Alexa 488-conjugated secondary antibody (green). Regions from the secondary dendrites are shown (Scale bar, 10 µm). (C) Regions from the secondary dendrites were analyzed for Pearson’s coefficient. Graph indicates mean ± SEM (n = 10 for CTL, n = 10 for KCl treatment). Statistics using an unpaired t test. n.s., not significant.